TurtleTree’s pitch deck is a highly professional example of how to leverage scientific authority and market timing in the biotech sector. Raising $30M in a Series A round in 2021, the company successfully positioned its 'Food 3.0' concept as a necessary evolution from plant-based alternatives. The deck excels at showcasing institutional validation, citing wins at the Entrepreneurship World Cup and Temasek Liveability Challenge. By highlighting a team of 21 scientists and 15 Ph.D.s, TurtleTree addresses the primary risk in deep-tech: execution capability. While the deck lacks granular unit eco…
Key takeaways
- The deck frames the industry evolution as Food 1.0 (factory farming), Food 2.0 (plant-based), and Food 3.0 (cell-based), positioning TurtleTree as the 'Revolution' on Slide 2.
- Market potential is segmented by application, showing a long-term total addressable market exceeding $125 billion across categories like infant nutrition and sports drinks on Slide 3.
- The company highlights significant historical funding, including a $6.2M pre-Series A and a $30M Series A tranche, as reported on Slide 4.
- Scientific credibility is the deck's core strength, boasting a team with 15 Ph.D.s and experience from companies like Novozymes and Merck KGaA on Slide 5.
- Geographic expansion is a key milestone, with the establishment of labs in Woodland (near UC Davis) and Boston (near MIT and Harvard) noted on Slide 4.
- The 'Buzz' slide (Slide 6) provides social proof through 250+ media mentions and features in CNN, Forbes, and The Scientist.
- Intellectual property is explicitly mentioned as a milestone, with the company having acquired IP assets and patents by 2021 on Slide 4.
- The deck omits a specific 'Ask' slide detailing the exact use of funds for the $30M round, focusing instead on past achievements and future market scale.
TurtleTree: Defining the 'Food 3.0' Era
TurtleTree’s Series A pitch deck is a masterclass in narrative positioning for a biotech startup. In an industry where the 'how' is often too complex for a generalist investor, TurtleTree focuses on the 'why' and the 'who.' By raising $30 million in 2021, the company proved that a clear vision of industry evolution, backed by a massive roster of Ph.D.s, can overcome the inherent risks of cellular agriculture. The deck, updated through May 2022, serves as both a fundraising tool and a progress report on their transition from a Singapore-founded startup to a global biotech player with significant US operations.
Slide 1: The Vision Statement
The title slide introduces the tagline 'Fixing Food with Food Intelligence.' It is a clean, modern design that avoids the typical 'cow in a field' imagery of traditional dairy. The use of the term 'Food Intelligence' is a strategic choice; it moves the conversation away from 'fake milk' and toward a high-tech, data-driven solution. This slide sets the tone for a company that views itself as a technology provider rather than just a food manufacturer.
Slide 2: The Intelligent Solution (Positioning)
Slide 2 is perhaps the most important strategic slide in the deck. It utilizes a '1.0, 2.0, 3.0' framework to categorize the food industry. Food 1.0 is defined as conventional agriculture, which the slide labels as 'wasteful, cruel, and unhealthy.' Food 2.0 covers plant-based and hybrid alternatives, but identifies a problem: a 'one-dimensional focus on sustainability compromises adoption.' This is a direct jab at competitors like Impossible Foods or Beyond Meat, suggesting their products lack the functional complexity of real dairy. Food 3.0 is TurtleTree’s territory: cell-based production built on 'Food Intelligence.' By positioning themselves as the 'Revolution,' they make plant-based alternatives look like a temporary stepping stone rather than the final destination.
Slide 3: Market Potential and Categories
Biotech investors need to see a path to massive scale to justify the R&D costs. Slide 3 provides a stacked bar chart showing the 'Market Value of Potential Applications.' The chart is divided into Short Term, Mid Term, and Long Term. The short-term focus is on Dietary Supplements and Nutrition (Protein) , which are high-margin, low-volume entry points. The long-term vision scales to over $125 billion , incorporating massive commodities like Fluid Milk and Infant Nutrition . This slide effectively communicates that while they are starting with specialized ingredients like lactoferrin, the technology platform is applicable to the entire dairy ecosystem.
Slide 4: The Milestone Roadmap
This slide is a dense timeline of execution. It tracks the company from its 2019 founding to its 2022 expansions. Key data points include:
2020: Secured US$6.2M in pre-Series A; won the Entrepreneurship World Cup (100,000 applicants). · 2021: Secured US$30M in Series A; hired Merck KGaA’s former R&D Director as CSO; set up Woodland R&D lab near UC Davis. · 2022: Opened Boston Lab near Tufts, MIT, and Harvard; established sales channels with 'key industry buyers.'
The mention of specific locations (UC Davis, MIT, Harvard) is a calculated move to signal that they are fishing in the best talent pools in the world.
Slide 5: The Science Team
In biotech, the team is the product. Slide 5 highlights Dr. Amanda Fischer (Ph.D. from UC Davis, 15 years at Novozymes) and Jung Yi (19 years at Novozymes). The slide then lists a staggering statistic: 21 scientists and 15 Ph.D.s . Below this, a 'logo wall' of former employers includes giants like Pfizer, Nestle, Merck, Google, and Microsoft. This slide is designed to eliminate 'execution risk' in the mind of the investor. It says: 'We have the people who have done this at the highest level for the world's biggest companies.'
Slide 6: The Buzz (Social Proof)
The final slide in the provided sequence focuses on external validation. It features logos from CNN, Forbes, and The Scientist . It also highlights individual accolades, such as CEO Fengru Lin being a Compass Awards 2022 Finalist and an advisor at Future Food-Tech New York. The claim of 'over 250 media mentions worldwide' serves to prove that the market is watching and that TurtleTree has captured the 'mindshare' of the industry.
What TurtleTree Does Well
TurtleTree excels at Institutional Validation . By winning major global competitions (Entrepreneurship World Cup, Temasek Liveability Challenge) and hiring from industry leaders like Merck and Novozymes, they build a 'moat of credibility.' In a field like cellular agriculture, where many companies struggle to move past the lab bench, TurtleTree uses its milestones to show a relentless pace of physical expansion (Woodland, Boston, Sacramento). The 'Food 3.0' narrative is also a brilliant piece of marketing, as it allows them to piggyback on the success of plant-based foods while simultaneously claiming to be superior to them.
What is Missing from the Deck
Despite the impressive scientific pedigree, the deck is light on Unit Economics . There is no mention of the current cost to produce a gram of lactoferrin versus the market price, nor is there a projected 'price parity' timeline. For a Series A, investors usually want to see a clear path to commercial viability. Additionally, the deck lacks a Competition Slide . While they categorize 'Food 2.0' as a problem, they do not name specific cell-based dairy competitors (like Perfect Day or Helaina), which would help an investor understand TurtleTree’s specific technical advantage. Finally, there is no Financial Ask or 'Use of Funds' slide in the provided materials, though the publisher reports the round was $30M.
Lessons for Founders
Founders in deep-tech or biotech should study TurtleTree’s Team Slide . Instead of just listing names, they lead with '21 scientists and 15 Ph.D.s,' which is a quantifiable metric of intellectual capital. Another takeaway is the Strategic Categorization of the market. By creating the 'Food 3.0' label, TurtleTree defined the rules of the game in a way that favored their technology. If you are entering a crowded space, don't just say you are better; create a new category that makes your competitors look obsolete. Lastly, the use of Geographic Signaling (mentioning proximity to UC Davis and MIT) is a low-cost way to boost perceived prestige and access to talent.
Frequently asked questions
- What is TurtleTree's core technology?
- TurtleTree develops cell-based food production technology, specifically targeting dairy ingredients like lactoferrin. As described on Slide 2, they refer to this as 'Food 3.0' or 'Food Intelligence,' which uses proprietary cellular agriculture to create functional nutrients that are identical to those found in traditional dairy but produced without factory farming.
- How much did TurtleTree raise with this deck?
- According to publisher-reported facts from Business Insider, TurtleTree raised $30 million in a Series A round in 2021. Slide 4 of the deck confirms this, noting they secured 'US$30M in first tranche of Series A funding,' which they claim was the largest Series A round in Asia's cell-based food sector at that time.
- Who are the key members of the TurtleTree team?
- The deck emphasizes a heavy scientific presence. Slide 5 highlights Dr. Amanda Fischer (Director of Strain Engineering) and Jung Yi (Director of Automation), both formerly of Novozymes. The team includes 21 scientists and 15 Ph.D.s, with additional leadership mentioned on Slide 6, including Chief Scientific Officer Dr. Aletta Schnitzler, formerly of Merck KGaA.
- What markets is TurtleTree targeting?
- Slide 3 outlines a broad range of high-value categories. Short-term targets include dietary supplements and protein nutrition. Mid-term targets expand into energy drinks and infant nutrition. Long-term, the company eyes massive markets like fluid milk, plant-based milk fortification, yogurt, and functional water, totaling over $125 billion in potential application value.
- What milestones has the company achieved?
- As of the 2022 update in the deck (Slide 4), TurtleTree had founded the company in 2019, won the Entrepreneurship World Cup, opened R&D labs in Woodland and Boston, acquired significant IP assets, and established sales channels with key industry buyers. They also completed the concept design for a Sacramento Pilot Facility.
